Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Myeloid Leukemia
100%
Protein Phosphatase 2A (PP2A)
100%
Tumor Suppressor Activity
100%
Blast Crisis
100%
Imatinib-resistant
100%
Leukemia Patients
44%
Imatinib
33%
Phosphatase
22%
Patient Cells
22%
Leukemogenesis
11%
Therapeutic Strategies
11%
Apoptosis
11%
Kinase Activity
11%
Tumor Protein p53 (TP53)
11%
New Drugs
11%
Disease Progression
11%
Disease Stage
11%
Chronic Phase
11%
Pharmacologic
11%
Leukemia Stem Cells
11%
Growth Suppression
11%
Blastic Transformation
11%
BCR-ABL
11%
Imatinib Mesylate
11%
Imatinib Therapy
11%
BCR-ABL Inhibitors
11%
Clonogenic Potential
11%
Abl Kinase
11%
Imatinib Resistance
11%
T315I
11%
Resistance to Imatinib
11%
Myeloid Progenitors
11%
Po-210
11%
BCR/ABL Fusion Gene
11%
Pharmacology, Toxicology and Pharmaceutical Science
Phosphoprotein Phosphatase 2A
100%
Tumor Suppressor Protein
100%
Chronic Myeloid Leukemia
100%
Blast Cell Crisis
100%
Imatinib
100%
Phosphotransferase
22%
Phosphatase
22%
Disease Exacerbation
11%
Leukemia
11%
Leukemogenesis
11%
Phosphotransferase Inhibitor
11%
Oncoprotein
11%
Diseases
11%